Ovarian Hyperstimulation Syndrome: Definition, Incidence, and Classification

 

 Buy Article Permissions and Reprints

ABSTRACT

Ovarian hyperstimulation syndrome (OHSS) is a iatrogenic complication of controlled ovarian stimulation. Although considered uncommon, the severe form is potentially fatal. Different clinical classifications have been developed through the years. No matter whether it is termed “grade C” or “critical” OHSS, life-threatening events may develop. Hence it is prudent to recognize the population at risk. Several risk factors for OHSS have been identified; some are considered major risk factors such as polycystic ovary syndrome; others are less well defined. Preventive measures could be taken before and during the treatment cycle while taking into consideration the patient's characteristics and the various treatment options and approaches that currently exist.

REFERENCES

• 1 Muller P. In: Beclere C Gonadotrophines en Gynécologie. Paris, France; Masson 1962: 137
  Google Scholar
• 2 Schenker J G, Weinstein D. Ovarian hyperstimulation syndrome: a current survey.  Fertil Steril. 1978;  30(3) 255-268
  PubMedGoogle Scholar
• 3 Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.  Hum Reprod Update. 2002;  8(6) 559-577
  CrossrefPubMedGoogle Scholar
• 4 Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction.  Fertil Steril. 2002;  77(4) 711-714
  CrossrefPubMedGoogle Scholar
• 5 Check J H, Wu C H, Gocial B, Adelson H G. Severe ovarian hyperstimulation syndrome from treatment with urinary follicle-stimulating hormone: two cases.  Fertil Steril. 1985;  43(2) 317-319
  PubMedGoogle Scholar
• 6 Hedon B, Out H J, Hugues J N et al. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.  Hum Reprod. 1995;  10(12) 3102-3106
  PubMedGoogle Scholar
• 7 European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone . Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial.  Fertil Steril. 2002;  78(3) 520-528
  CrossrefPubMedGoogle Scholar
• 8 Schenker J G, Ezra Y. Complications of assisted reproductive techniques.  Fertil Steril. 1994;  61(3) 411-422
  PubMedGoogle Scholar
• 9 Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review.  Obstet Gynecol Surv. 1989;  44(6) 430-440
  CrossrefPubMedGoogle Scholar
• 10 Brinsden P R, Wada I, Tan S L, Balen A, Jacobs H S. Diagnosis, prevention and management of ovarian hyperstimulation syndrome.  Br J Obstet Gynaecol. 1995;  102(10) 767-772
  PubMedGoogle Scholar
• 11 Morris R S, Paulson R J, Sauer M V, Lobo R A. Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome.  Hum Reprod. 1995;  10(4) 811-814
  PubMedGoogle Scholar
• 12 Abramov Y, Elchalal U, Schenker J G. Severe OHSS: An ‘epidemic’ of severe OHSS: a price we have to pay?.  Hum Reprod. 1999;  14(9) 2181-2183
  CrossrefPubMedGoogle Scholar
• 13 Klemetti R, Sevón T, Gissler M, Hemminki E. Complications of IVF and ovulation induction.  Hum Reprod. 2005;  20(12) 3293-3300
  CrossrefPubMedGoogle Scholar
• 14 Delvigne A. Symposium: update on prediction and management of OHSS. Epidemiology of OHSS.  Reprod Biomed Online. 2009;  19(1) 8-13
  CrossrefPubMedGoogle Scholar
• 15 Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.  Fertil Steril. 1999;  71(5) 808-814
  CrossrefPubMedGoogle Scholar
• 16 Delvigne A, Dubois M, Battheu B et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction.  Hum Reprod. 1993;  8(9) 1361-1366
  PubMedGoogle Scholar
• 17 Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review.  Obstet Gynecol Surv. 1989;  44(6) 430-440
  CrossrefPubMedGoogle Scholar
• 18 Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth E J. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome.  Am J Obstet Gynecol. 1988;  159(1) 210-215
  PubMedGoogle Scholar
• 19 Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization.  Am J Health Syst Pharm. 2008;  65(12) 1148-1153
  CrossrefPubMedGoogle Scholar
• 20 Lewis C G, Warnes G M, Wang X J, Matthews C D. Failure of body mass index or body weight to influence markedly the response to ovarian hyperstimulation in normal cycling women.  Fertil Steril. 1990;  53(6) 1097-1099
  PubMedGoogle Scholar
• 21 Delvigne A, Demoulin A, Smitz J et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.  Hum Reprod. 1993;  8(9) 1353-1360
  CrossrefPubMedGoogle Scholar
• 22 Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures.  Hum Reprod. 1992;  7(3) 320-327
  PubMedGoogle Scholar
• 23 Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.  Fertil Steril. 1992;  58(2) 249-261
  PubMedGoogle Scholar
• 24 Kamat B R, Brown L F, Manseau E J, Senger D R, Dvorak H F. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development.  Am J Pathol. 1995;  146(1) 157-165
  PubMedGoogle Scholar
• 25 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.  Fertil Steril. 2004;  81(1) 19-25
  PubMedGoogle Scholar
• 26 Bettendorf G, Lindner C. The ovarian hyperstimulation syndrome.  Horm Metab Res. 1987;  19(11) 519-522
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Gustafson O, Carlström K, Nylund L. Androstenedione as a predictor of ovarian hyperstimulation syndrome.  Hum Reprod. 1992;  7(7) 918-921
  PubMedGoogle Scholar
• 28 Bódis J, Török A, Tinneberg H R. LH/FSH ratio as a predictor of ovarian hyperstimulation syndrome.  Hum Reprod. 1997;  12(4) 869-870
  CrossrefPubMedGoogle Scholar
• 29 Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS.  Hum Reprod. 2003;  18(6) 1140-1141
  CrossrefPubMedGoogle Scholar
• 30 Haning Jr R V, Austin C W, Carlson I H, Kuzma D L, Shapiro S S, Zweibel W J. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins.  Fertil Steril. 1983;  40(1) 31-36
  PubMedGoogle Scholar
• 31 Asch R H, Li H P, Balmaceda J P, Weckstein L N, Stone S C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups.  Hum Reprod. 1991;  6(10) 1395-1399
  CrossrefPubMedGoogle Scholar
• 32 Mathur R S, Akande A V, Keay S D, Hunt L P, Jenkins J M. Distinction between early and late ovarian hyperstimulation syndrome.  Fertil Steril. 2000;  73(5) 901-907
  CrossrefPubMedGoogle Scholar
• 33 Levy T, Orvieto R, Homburg R, Peleg D, Dekel A, Ben-Rafael Z. Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient.  Hum Reprod. 1996;  11(6) 1177-1179
  PubMedGoogle Scholar
• 34 Rizk B, Aboulghar M. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P A Textbook of in Vitro Fertilization and Assisted Reproduction. 2nd ed. Lancaster, United Kingdom; Parthenon 1999: 131-155
  Google Scholar
• 35 Aboulghar M. Symposium: Update on prediction and management of OHSS. Prevention of OHSS.  Reprod Biomed Online. 2009;  19(1) 33-42
  CrossrefPubMedGoogle Scholar
• 36 Orvieto R, Achiron A, Margalit R, Ben-Rafael Z. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome.  J Assist Reprod Genet. 1998;  15(1) 46-49
  CrossrefPubMedGoogle Scholar
• 37 Sher G, Zouves C, Feinman M, Maassarani G. ‘Prolonged coasting’: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.  Hum Reprod. 1995;  10(12) 3107-3109
  PubMedGoogle Scholar
• 38 Benadiva C A, Davis O, Kligman I, Moomjy M, Liu H C, Rosenwaks Z. Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 1997;  67(4) 724-727
  CrossrefPubMedGoogle Scholar
• 39 Haas G G, Seibel M M. Human menopausal gonadotropins for ovulation induction, intrauterine insemination and assisted reproduction. In: Seibel MM, Blackwell RE Ovulation Induction. New York, NY; Raven 1994: 117-133
  Google Scholar
• 40 Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos.  Hum Reprod. 2003;  18(4) 665-667
  CrossrefPubMedGoogle Scholar
• 41 Blankstein J, Shalev J, Saadon T et al. Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles.  Fertil Steril. 1987;  47(4) 597-602
  PubMedGoogle Scholar
• 42 Jayaprakasan K, Herbert M, Moody E, Stewart J A, Murdoch A P. Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research.  Hum Fertil (Camb). 2007;  10(3) 183-187
  CrossrefPubMedGoogle Scholar
• 43 Verwoerd G R, Mathews T, Brinsden P R. Optimal follicle and oocyte numbers for cryopreservation of all embryos in IVF cycles at risk of OHSS.  Reprod Biomed Online. 2008;  17(3) 312-317
  CrossrefPubMedGoogle Scholar
• 44 Papanikolaou E G, Pozzobon C, Kolibianakis E M et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.  Fertil Steril. 2006;  85(1) 112-120
  CrossrefPubMedGoogle Scholar
• 45 Forman R G, Frydman R, Egan D, Ross C, Barlow D H. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention.  Fertil Steril. 1990;  53(3) 502-509
  PubMedGoogle Scholar
• 46 Tal J, Paz B, Samberg I, Lazarov N, Sharf M. Ultrasonographic and clinical correlates of menotropin versus sequential clomiphene citrate: menotropin therapy for induction of ovulation.  Fertil Steril. 1985;  44(3) 342-349
  PubMedGoogle Scholar
• 47 Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani P G. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.  Hum Reprod. 2005;  20(9) 2421-2425
  CrossrefPubMedGoogle Scholar
• 48 Whelan III J G, Vlahos N F. The ovarian hyperstimulation syndrome.  Fertil Steril. 2000;  73(5) 883-896
  CrossrefPubMedGoogle Scholar
• 49 Laufer N, Simon A, Hurwitz A, Glaststein I Z. In vitro fertilization. In: Seibel MM Infertility: A Comprehensive Text. 2nd ed. Norwalk, CT; Appleton & Lange 1997: 703-736
  Google Scholar
• 50 MacDougall M J, Tan S L, Jacobs H S. In-vitro fertilization and the ovarian hyperstimulation syndrome.  Hum Reprod. 1992;  7(5) 597-600
  PubMedGoogle Scholar
• 51 Kol S, Dor J. Symposium: Update on prediction and management of OHSS. Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation.  Reprod Biomed Online. 2009;  19(1) 59-60
  CrossrefPubMedGoogle Scholar
• 52 Al-Inany H G, Aboulghar M, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception.  Cochrane Database Syst Rev. 2001;  (4) CD001750
  PubMedGoogle Scholar
• 53 Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem A C. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization.  Hum Reprod. 1990;  5(8) 933-937
  PubMedGoogle Scholar
• 54 Rabau E, David A, Serr D M, Mashiach S, Lunenfeld B. Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment.  Am J Obstet Gynecol. 1967;  98(1) 92-98
  PubMedGoogle Scholar
• 55 Report of a WHO scientific group . Agents stimulating gonadal function in the human. Report of a WHO scientific group.  World Health Organ Tech Rep Ser. 1973;  514 1-30
  PubMedGoogle Scholar
• 56 Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS.  Reprod Biomed Online. 2009;  19(1) 28-32
  CrossrefPubMedGoogle Scholar
• 57 Lyons C A, Wheeler C A, Frishman G N, Hackett R J, Seifer D B, Haning Jr R V. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.  Hum Reprod. 1994;  9(5) 792-799
  PubMedGoogle Scholar
• 58 Papanikolaou E G, Tournaye H, Verpoest W et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile.  Hum Reprod. 2005;  20(3) 636-641
  CrossrefPubMedGoogle Scholar
• 59 Lee K H, Kim S H, Jee B C et al. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome.  Fertil Steril. 2010;  93(7) 2274-2280
  CrossrefPubMedGoogle Scholar
• 60 Check J H, Choe J K, Nazari A. Hyperreactio luteinalis despite the absence of a corpus luteum and suppressed serum follicle stimulating concentrations in a triplet pregnancy.  Hum Reprod. 2000;  15(5) 1043-1045
  CrossrefPubMedGoogle Scholar
• 61 Ludwig M, Gembruch U, Bauer O, Diedrich K. Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS.  Hum Reprod. 1998;  13(8) 2082-2087
  CrossrefPubMedGoogle Scholar
• 62 Rizk B. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome.  Reprod Biomed Online. 2009;  19(1) 14-27
  CrossrefPubMedGoogle Scholar
• 63 Delbaere A, Smits G, Olatunbosun O, Pierson R, Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?.  Hum Reprod. 2004;  19(3) 486-489
  CrossrefPubMedGoogle Scholar

Einat ZiviM.D. 

Department of Obstetrics and Gynecology, Hadassah University Hospital

Jerusalem, Israel

Email: zivi_e@hotmail.com